Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics Strikes Deals With Quest, LabCorp

NEW YORK, Oct. 2 - Celera Diagnostics today said it has signed a pair of collaborations with Quest Diagnostics and Laboratory Corporation of America to determine the "clinical utility" of lab tests for a variety of diseases.


Terms of the deal call for Quest to receive exclusive yet temporary access to markers with potential clinical usefulness in cardiovascular disease and diabetes. LabCorp gets that deal but only for Alzheimer's disease and breast and prostate cancer.


In exchange, Celera Diagnostics, which will run the disease association studies for the collaboration in-house, said it will become "a preferred vendor" to both clinical diagnostics powerhouses.


Click here for more information on the LabCorp deal, and here for the Quest deal.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.